CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029
The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029. Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.
“Yescarta segment accounted for the highest share of 2023.”
Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.
“The Hospitals End User segment held the dominant share in the CAR T-cell therapy market.”
Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.
“Asia Pacific region estimated to show fastest growth rate.”
The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific’s progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“Yescarta segment accounted for the highest share of 2023.”
Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.
“The Hospitals End User segment held the dominant share in the CAR T-cell therapy market.”
Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.
“Asia Pacific region estimated to show fastest growth rate.”
The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific’s progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70%, and Demand Side - 30%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%
- Bristol-Myers Squibb Company (US)
- Gilead Sciences Inc. (US)
- Novartis AG (Switzerland)
- Johnson & Johnson (US)
- CARsgen Therapeutics Holdings Limited (China)
- IASO Biotherapeutics (China)
- JW (Cayman) Therapeutics Co. Ltd (China)
- ImmunoAct (India)
- CRISPR Therapeutics (Switzerland)
- Autolus Therapeutics (UK)
- Allogene Therapeutics (US)
- Cartesian Therapeutics Inc. (US)
- Guangzhou Bio-gene Technology Co. Ltd (China)
- Wugen (US).
This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.
- Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the CAR T-cell therapy market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 GROWTH RATE ASSUMPTIONS
2.3.1 CAGR PROJECTIONS
2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4 VOLUME ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH LIMITATIONS
2.7 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CAR T-CELL THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023)
4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT
4.4 CAR T-CELL THERAPY MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing cancer prevalence
5.2.1.2 Technological advancements in CAR T-cell therapies
5.2.1.3 Rising investment and funding for therapy development
5.2.2 RESTRAINTS
5.2.2.1 High therapy costs
5.2.2.2 Adverse effects
5.2.3 OPPORTUNITIES
5.2.3.1 Expansion into solid tumors
5.2.3.2 Collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Patient recruitment for trials
5.2.4.2 Reimbursement issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 PRODUCTS
5.5.2 END USERS
5.5.3 REGULATORY BODIES
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 CAR DESIGN AND OPTIMIZATION
5.6.1.2 VIRAL VECTOR TECHNOLOGY
5.6.1.3 CELL CULTURE AND EXPANSION TECHNIQUES
5.6.2 COMPLIMENTARY TECHNOLOGIES
5.6.2.1 GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 MONITORING AND IMAGING TECHNOLOGIES
5.7 PATENT ANALYSIS
5.7.1 METHODOLOGY
5.7.2 NUMBER OF PATENTS FILED
5.7.3 INNOVATION AND PATENT APPLICATIONS
5.7.4 TOP APPLICANTS
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE, BY TYPE
5.8.2 AVERAGE SELLING PRICE, BY REGION
5.8.3 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.9 KEY CONFERENCES & EVENTS, 2024–2O25
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY SCENARIO
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 INVESTMENT & FUNDING SCENARIO
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY BUYING CRITERIA
6 CAR T-CELL THERAPY MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 YESCARTA
6.2.1 INCREASING REACH TO DRIVE MARKET
6.3 KYMRIAH
6.3.1 APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH
6.4 CARVYKTI
6.4.1 WIDESPREAD REACH TO ENSURE MARKET GROWTH
6.5 ABECMA
6.5.1 RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET
6.6 TECARTUS
6.6.1 GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT
TO PROPEL MARKET
6.7 BREYANZI
6.7.1 MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
6.8 OTHER PRODUCTS
7 CAR T-CELL THERAPY MARKET, BY TARGET
7.1 INTRODUCTION
7.2 CD19
7.2.1 RISING INDICATIONS IN PIPELINE TO DRIVE MARKET
7.3 BCMA
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH
7.4 OTHER TARGETS
8 CAR T-CELL THERAPY MARKET, BY INDICATION
8.1 INTRODUCTION
8.2 MULTIPLE MYELOMA
8.2.1 RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET
8.3 B-CELL LYMPHOMA
8.3.1 RISING PREVALENCE TO PROPEL MARKET GROWTH
8.4 ACUTE LYMPHOBLASTIC LEUKEMIA
8.4.1 FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET
8.5 OTHER INDICATIONS
9 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC
9.1 INTRODUCTION
9.2 ADULTS
9.2.1 INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET
9.3 PEDIATRICS
9.3.1 RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH
10 CAR T-CELL THERAPY MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS
10.2.1 GROWING PREVALENCE OF CANCER TO DRIVE MARKET
10.3 SPECIALTY CENTERS
10.3.1 GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET
10.4 LONG-TERM CARE FACILITIES
10.4.1 GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET
11 CAR T-CELL THERAPY MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Rising R&D activities for CAR T-cell therapies to drive market
11.2.3 CANADA
11.2.3.1 Government initiatives for regenerative medicine research to drive market
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Rising focus on clinical research to drive market
11.3.3 UK
11.3.3.1 Rising technological advancements in automation to drive market
11.3.4 FRANCE
11.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
11.3.5 ITALY
11.3.5.1 Growth in biotech sector to drive market
11.3.6 SPAIN
11.3.6.1 Rising focus on cell therapies to support market growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Rising number of CAR T-cell clinical trials to support market growth
11.4.3 JAPAN
11.4.3.1 Increasing product approvals to drive market
11.4.4 INDIA
11.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
11.4.5 AUSTRALIA
11.4.5.1 Robust infrastructure for clinical trials and well-developed healthcare sector to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Rising growth in biopharmaceutical industry to drive market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 High expenditure on healthcare to support market growth
11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL
THERAPY MARKET
12.3 REVENUE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.4.1 RANKING OF KEY MARKET PLAYERS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Product footprint
12.5.5.3 Target footprint
12.5.5.4 Indication footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 BRISTOL-MYERS SQUIBB COMPANY
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product approvals
13.1.1.3.2 Deals
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 GILEAD SCIENCES, INC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product approvals
13.1.2.3.2 Deals
13.1.2.3.3 Other developments
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 NOVARTIS AG
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches & approvals
13.1.3.3.2 Expansions
13.1.3.3.3 Other developments
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 JOHNSON & JOHNSON
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product approvals
13.1.4.3.2 Deals
13.1.5 JW (CAYMAN) THERAPEUTICS CO. LTD.
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product approvals
13.1.5.3.2 Deals
13.1.6 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.6.3.2 Other developments
13.1.7 CARSGEN THERAPEUTICS HOLDINGS LIMITED
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product approvals
13.1.7.3.2 Deals
13.1.7.3.3 Expansions
13.1.8 IASO BIOTHERAPEUTICS
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product approvals
13.1.8.3.2 Deals
13.2 OTHER PLAYERS
13.2.1 GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.)
13.2.2 CARTESIAN THERAPEUTICS, INC.
13.2.3 AUTOLUS THERAPEUTICS
13.2.4 ALLOGENE THERAPEUTICS
13.2.5 CRISPR THERAPEUTICS
13.2.6 WUGEN
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 GROWTH RATE ASSUMPTIONS
2.3.1 CAGR PROJECTIONS
2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4 VOLUME ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH LIMITATIONS
2.7 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CAR T-CELL THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023)
4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT
4.4 CAR T-CELL THERAPY MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing cancer prevalence
5.2.1.2 Technological advancements in CAR T-cell therapies
5.2.1.3 Rising investment and funding for therapy development
5.2.2 RESTRAINTS
5.2.2.1 High therapy costs
5.2.2.2 Adverse effects
5.2.3 OPPORTUNITIES
5.2.3.1 Expansion into solid tumors
5.2.3.2 Collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Patient recruitment for trials
5.2.4.2 Reimbursement issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 PRODUCTS
5.5.2 END USERS
5.5.3 REGULATORY BODIES
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 CAR DESIGN AND OPTIMIZATION
5.6.1.2 VIRAL VECTOR TECHNOLOGY
5.6.1.3 CELL CULTURE AND EXPANSION TECHNIQUES
5.6.2 COMPLIMENTARY TECHNOLOGIES
5.6.2.1 GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 MONITORING AND IMAGING TECHNOLOGIES
5.7 PATENT ANALYSIS
5.7.1 METHODOLOGY
5.7.2 NUMBER OF PATENTS FILED
5.7.3 INNOVATION AND PATENT APPLICATIONS
5.7.4 TOP APPLICANTS
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE, BY TYPE
5.8.2 AVERAGE SELLING PRICE, BY REGION
5.8.3 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.9 KEY CONFERENCES & EVENTS, 2024–2O25
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY SCENARIO
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 INVESTMENT & FUNDING SCENARIO
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY BUYING CRITERIA
6 CAR T-CELL THERAPY MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 YESCARTA
6.2.1 INCREASING REACH TO DRIVE MARKET
6.3 KYMRIAH
6.3.1 APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH
6.4 CARVYKTI
6.4.1 WIDESPREAD REACH TO ENSURE MARKET GROWTH
6.5 ABECMA
6.5.1 RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET
6.6 TECARTUS
6.6.1 GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT
TO PROPEL MARKET
6.7 BREYANZI
6.7.1 MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
6.8 OTHER PRODUCTS
7 CAR T-CELL THERAPY MARKET, BY TARGET
7.1 INTRODUCTION
7.2 CD19
7.2.1 RISING INDICATIONS IN PIPELINE TO DRIVE MARKET
7.3 BCMA
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH
7.4 OTHER TARGETS
8 CAR T-CELL THERAPY MARKET, BY INDICATION
8.1 INTRODUCTION
8.2 MULTIPLE MYELOMA
8.2.1 RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET
8.3 B-CELL LYMPHOMA
8.3.1 RISING PREVALENCE TO PROPEL MARKET GROWTH
8.4 ACUTE LYMPHOBLASTIC LEUKEMIA
8.4.1 FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET
8.5 OTHER INDICATIONS
9 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC
9.1 INTRODUCTION
9.2 ADULTS
9.2.1 INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET
9.3 PEDIATRICS
9.3.1 RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH
10 CAR T-CELL THERAPY MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS
10.2.1 GROWING PREVALENCE OF CANCER TO DRIVE MARKET
10.3 SPECIALTY CENTERS
10.3.1 GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET
10.4 LONG-TERM CARE FACILITIES
10.4.1 GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET
11 CAR T-CELL THERAPY MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Rising R&D activities for CAR T-cell therapies to drive market
11.2.3 CANADA
11.2.3.1 Government initiatives for regenerative medicine research to drive market
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Rising focus on clinical research to drive market
11.3.3 UK
11.3.3.1 Rising technological advancements in automation to drive market
11.3.4 FRANCE
11.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
11.3.5 ITALY
11.3.5.1 Growth in biotech sector to drive market
11.3.6 SPAIN
11.3.6.1 Rising focus on cell therapies to support market growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Rising number of CAR T-cell clinical trials to support market growth
11.4.3 JAPAN
11.4.3.1 Increasing product approvals to drive market
11.4.4 INDIA
11.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
11.4.5 AUSTRALIA
11.4.5.1 Robust infrastructure for clinical trials and well-developed healthcare sector to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Rising growth in biopharmaceutical industry to drive market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 High expenditure on healthcare to support market growth
11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL
THERAPY MARKET
12.3 REVENUE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.4.1 RANKING OF KEY MARKET PLAYERS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Product footprint
12.5.5.3 Target footprint
12.5.5.4 Indication footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 BRISTOL-MYERS SQUIBB COMPANY
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product approvals
13.1.1.3.2 Deals
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 GILEAD SCIENCES, INC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product approvals
13.1.2.3.2 Deals
13.1.2.3.3 Other developments
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 NOVARTIS AG
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches & approvals
13.1.3.3.2 Expansions
13.1.3.3.3 Other developments
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 JOHNSON & JOHNSON
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product approvals
13.1.4.3.2 Deals
13.1.5 JW (CAYMAN) THERAPEUTICS CO. LTD.
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product approvals
13.1.5.3.2 Deals
13.1.6 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.6.3.2 Other developments
13.1.7 CARSGEN THERAPEUTICS HOLDINGS LIMITED
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product approvals
13.1.7.3.2 Deals
13.1.7.3.3 Expansions
13.1.8 IASO BIOTHERAPEUTICS
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product approvals
13.1.8.3.2 Deals
13.2 OTHER PLAYERS
13.2.1 GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.)
13.2.2 CARTESIAN THERAPEUTICS, INC.
13.2.3 AUTOLUS THERAPEUTICS
13.2.4 ALLOGENE THERAPEUTICS
13.2.5 CRISPR THERAPEUTICS
13.2.6 WUGEN
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
